100 signatures reached
To: Sage Therapeutics and Biogen Inc.
Make Zurzuvae affordable and accessible
Zurzuvae is the first-ever pill for treating postpartum depression that Sage Therapeutics and Biogen Inc. developed. This breakthrough offers a glimmer of hope to countless parents grappling with this serious condition. But here's the thing – unsurprisingly, Zurzuvae might end up being pretty expensive. And that's a big concern since postpartum depression already throws a hefty emotional burden on parents and families and the price tag could add a huge load of stress.
The latest reports suggest that Zurzuvae will be going for $11,000 per patient for a two-week treatment course for postpartum depression. – that’s not something we can overlook. It’s a price tag that could put this essential medication out of reach for many parents who need it the most. We've seen how Big Pharma often plays the same old game – introducing groundbreaking medications with sky-high prices. The well-being of parents should never be compromised for profit.
We demand that Sage Therapeutics and Biogen Inc., the companies behind Zurzuvae, to make this groundbreaking medication affordable to all parents, not just those who can afford it.
Why is this important?
Not only the accessibility of a groundbreaking medication for postpartum depression at stake but also the fundamental principle that healthcare should be a right, not a luxury. The estimated exorbitant price of Zurzuvae threatens to deny countless parents the relief they desperately need during one of the most vulnerable periods of their lives. By signing this petition, we are sending a strong message to pharmaceutical companies that the well-being of individuals should never be compromised for profit margins. This is a pivotal moment to demand a change in the pharmaceutical industry's practices, to ensure that essential medical advancements are accessible to all, regardless of their financial status.